(Breast Cancer) S-1 Combined With Hormone Therapy: Is It Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
- February 1, 2021
- 1 min read
On January 25, Kyoto University announced results from a clinical trial evaluating the combination of oral fluoropyrimidine S-1 with hormone therapy as post-operative treatment for primary breast cancer patients with hormone receptor (HR)-positive, HER2-negative disease. This regimen shows promise as a new treatment option for patients at moderate to high risk of recurrence. Detailed findings were published in the English-language scientific journal The Lancet.
Breast cancer is the most prevalent cancer among women. The most common subtype, comprising approximately 70% of cases, is HR-positive, HER2-negative breast cancer. The standard post-operative treatment for these patients involves at least 5 years of hormone therapy. While improvements in screening and pharmacotherapy have enhanced overall breast cancer prognosis, there remains room for improvement due to the ongoing risk of recurrence following surgery.
To improve outcomes, approaches such as extended hormone therapy duration and combination chemotherapy have been explored. S-1 has demonstrated efficacy in suppressing disease progression in metastatic breast cancer. Therefore, the research team conducted a clinical trial to evaluate whether S-1 combined with post-operative hormone therapy could improve outcomes in HR+, HER2-negative primary breast cancer patients.
The study data demonstrate that S-1 combined with hormone therapy represents a promising new treatment option for HR+, HER2-negative primary breast cancer patients at moderate to high risk of recurrence. Future work will include long-term follow-up to assess survival outcomes with this combination regimen.
Source: https://this.kiji.is/726692910398849024
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4